|Publication number||US5424286 A|
|Application number||US 08/066,480|
|Publication date||Jun 13, 1995|
|Filing date||May 24, 1993|
|Priority date||May 24, 1993|
|Publication number||066480, 08066480, US 5424286 A, US 5424286A, US-A-5424286, US5424286 A, US5424286A|
|Original Assignee||Eng; John|
|Export Citation||BiBTeX, EndNote, RefMan|
|Non-Patent Citations (15), Referenced by (274), Classifications (12), Legal Events (10) |
|External Links: USPTO, USPTO Assignment, Espacenet|
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US 5424286 A
This invention encompasses pharmaceutical compositions containing exendin-3 or exendin-4, fragments thereof, or any combination thereof, and methods for the treatment of diabetes mellitus and the prevention of hyperglycemia.
What is claimed is:
1. A polypeptide having the amino acid sequence:
HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG P[SEQ ID No:3].
2. A polypeptide having the amino acid sequence:
HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG Y[SEQ ID No:4].
3. A pharmaceutical composition which comprises an effective insulinotropic amount of a substantially pure polypeptide, synthetic or purified from natural sources, having the amino acid sequence of claim 1 in a suitable carrier, which will stimulate the secretion of insulin in vivo.
4. A pharmaceutical composition which comprises an effective insulinotropic amount of a substantially pure polypeptide, synthetic or purified form natural sources, having the amino acid sequence of claim 2 in a suitable carrier, which will stimulate the secretion of insulin in vivo.
5. A method of stimulating insulin release in a mammal comprising administering an effective insulinotropic amount of a substantially pure polypeptide, synthetic or purified from natural sources, having the amino acid sequence:
HSDGTFITSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPPS (SEQ ID NO: 1),
wherein the resulting insulinotropic effect is greater than that attainable by administration of GLP-1.
6. A method of stimulating insulin release in a mammal comprising administering an effective insulinotropic amount of a substantially pure polypeptide, synthetic or purified from natural sources, having the amino acid sequence:
HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPPS (SEQ ID NO: 2),
wherein the resulting insulinotropic effect is greater than that attainable by administration of GLP-1.
7. A method of inhibiting insulin release in a mammal comprising administering an effective amount of a substantially pure polypeptide, synthetic or purified from natural sources, having the amino acid sequence:
DL SKQMEEEAVR LFIEWLKNGG PSSGAPPPS (SEQ ID NO: 5).
This U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of the agreement with the Department of Veterans Affairs, reference number 024I, GPB No. 20-560.
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is in the field of the prevention and treatment of diabetes mellitus.
2. Description of the Prior Art
Diabetes mellitus (DM) is a major chronic illness found in humans with many consequences. Some complications arising from long-standing diabetes are blindness, kidney failure, and limb amputations. Insulin-dependent diabetes mellitus (IDDM) accounts for 10 to 15% of all cases of diabetes mellitus. The action of IDDM is to cause hyperglycemia (elevated blood glucose concentration) and a tendency towards diabetic ketoacidosis (DKA). Currently treatment requires chronic administration of insulin. Non-insulin dependent diabetes mellitus (NIDDM) is marked by hyperglycemia that is not linked with DKA. Sporadic or persistent incidence of hyperglycemia can be controlled by administering insulin. Uncontrolled hyperglycemia can damage the cells of the pancreas which produce insulin (the β-islet cells) and in the long term create greater insulin deficiencies. Currently, oral sulfonylureas and insulin are the only two therapeutic agents available in the United States. for treatment of Diabetes mellitus. Both agents have the potential for producing hypoglycemia as a side effect, reducing the blood glucose concentration to dangerous levels. There is no generally applicable and consistently effective means of maintaining an essentially normal fluctuation in glucose levels in DM. The resultant treatment attempts to minimize the risks of hypoglycemia while keeping the glucose levels below a target value. The drug regimen is combined with control of dietary intake of carbohydrates to keep glucose levels in control.
A fragment of human peptide molecule called, glucagon-like peptide-1 (GLP-1) has been found to be a glucose-dependent insulinotropic agent (Gutniak, M., et al. N. Engl. J. Bled. 1992; 326:1316-1322). GLP-1 is itself a fragment of the human proglucagon molecule. Another active fragment, glucagon-like insulinotropic peptide (GLIP), corresponds to GLP-1(7-36). It was reasoned that since GLIP is the naturally active form found in humans after a meal, this peptide may aid in glucose regulation in IDDM and NIDDM.
In normal subjects, the infusion of GLIP significantly lowered the meal-related increases in blood glucose concentration, and the plasma concentrations of insulin and glucagon. In patients with NIDDM, the treatment reduced the requirement for insulin by 8 fold. In patients with IDDM, the GLIP treatment lowered the insulin required by one half. This glucose-dependent activity is a very desirable characteristic for a therapeutic agent that can be used to treat DM avoiding tile complications of hypoglycemic side effects.
In 1981, it was discovered that Gila monster (Heloderma suspectum) venom stimulated pancreatic enzyme secretion in vitro (Raufman, J. P., et al., Gastroenterology 80:1257 abst. (1981); Raufman, J. P., et al., Am. J. Physiol. 242: G470-G474 (1982)). Several peptides have been isolated from the venom that can stimulate increased cAMP and amylase release from dispersed pancreatic acinar cells. These structural analogs to the mammalian peptides VIP (vasoactive intestinal peptide) and secretin include helospectin-I, helospectin-II (Parker, D. S. et al., J. Biol. Chem. 259:11751-11755 (1984)),and helodermin (Hoshino, M. et al., FEBS Lett. 178:233-239 (1984)). Recently, we discovered another peptide that increases cAMP and stimulated the release of amylase in dispersed acinar cells. This peptide was found in Heloderma horridum venom and was termed exendin-3 (Eng, J. et al., J. BIol. Chem. 265: 20259-20262 (1990). Exendin-3 shares homology with VIP, secretin, helospectin-I and -II, and helodermin. The venom of Heloderma suspectum was examined and another peptide was purified from it. This peptide called exendin-4 is an analogue of exendin-3 with an identical sequence except for substitutions in residues 2 and 3 from the amino terminus (Eng, J. et al.,J. Biol. Chem. 267:742-7405 (1992)). Experiments were done to establish that the exendins could stimulate cAMP activity in dispersed pancreatic acinar cells, and a specific antagonist, exendin(9-39) amide, which can inhibit the effects of the exendins, was identified. (Raufman, J. P. et al., J. BIol. Chem. 266: 2897-2902 (1991 )) Experiments were performed to establish that GLP-1 could interact with possible exendin receptors in dispersed pancreatic acinar cells in vitro (Raufman, J. P. et al., J. BIol. Chem. 267:21432-21437 (1992)).
SUMMARY OF THE INVENTION
This invention encompasses pharmaceutical compositions containing exendin-3 or exendin-4, or any combination thereof, and methods for the treatment of diabetes mellitus and the prevention of hyperglycemia.
The compositions of the invention will normalize hyperglycemia through glucose-dependent, insulin-dependent and insulin-independent mechanisms. Therefore they will be useful as primary agents for the treatment of type II diabetes mellitus and as adjunctive agents for the treatment of type I diabetes mellitus. The invention specifically provides for exendin-4(1-39) as an insulinotropic agent.
The use of an effective amount of exendins as a treatment for diabetes mellitus has the advantage of being more potent than other insulinotropic peptides. The present invention is especially suited for the treatment of patients with diabetes, both type I and type II, in that the action of the peptide is dependent on the glucose concentration of the blood, and thus the risk of hypoglycemic side effects are greatly reduced over the risks in using current methods of treatment. Thus the use of insulinotropic peptides such as exendin-3 and exendin-4, has many advantages in the treatment of diabetes mellitus over current methods.
The present invention also provides for inhibitory agents derived from the exendins. In particular, exendin-4(9-39) as an inhibitor of exendin-4 and GLP-1 insulinotropic activity.
The present invention also provides for a method for treating diabetes mellitus in an individual, wherein said method comprises providing an amount of an insulinotropic composition sufficient to treat said diabetes; said composition containing an insulinotropic molecule; wherein said molecule is selected from the group consisting of:
(a) a peptide having the amino acid sequence substantially identicle to the sequence of exendin-3 or exendin-4 or fragments thereof; and
(b) a derivative of said peptide (a), wherein said derivative is selected from the group consisting of:
(1) a pharmaceutically acceptable acid addition salt of said peptide;
(2) a pharmaceutically acceptable carboxylate salt of said peptide;
(3) a pharmaceutically acceptable lower alkyl ester of said peptide; and,
(4) a pharmaceutically acceptable amide of said peptide wherein said pharmaceutically acceptable amide is selected from the group consisting of amide, lower alkyl amide and lower dialkyl amide; wherein said molecule has an insulinotropic activity which exceeds the insulinotropic activity of exendin-3 or exendin-4 or fragments thereof.
Thus the invention provides for the peptides or peptide fragments, made synthetically or purified from natural sources, which embody the biological activity of the exendins, or fragments thereof, as described by the present specification.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a graph showing exendin stimulated insulin secretion in a dog. Endogenous insulin secretion stimulated by exendin-3 (200 nmol) in a conscious dog. Exendin-3 was given as a bolus injection into a leg vain at time 0. Plasma was measured by radioimmunoassay.
FIG. 2a & 2b & 2c are graphs showing the serial injection of GLP-1 and Exendin-4. FIG. 2a, Dog #1. FIG. 2b, Dog #2. FIG. 2c, Dog #3. Serial injections of GLP-1(7-36) amide alternating with exendin-4 into the left atrium via a chronically indwelling catheter. GLP-1(7-36) amide was given at time 0 (0.1 nmol) and at 40 min (1 nmol). Exendin-4 was given at 20 min (0.1 nmol) and at 60 min (1 nmol). In 2c, the rise and fall in the baseline insulin between time 0 and 60 min is unexplained.
FIG. 3 is a graph illustrating the effect of exendin with and without antagonist. Insulin response in a normal dog to exendin-4 with or without exendin(9-39) amide. Glucose was infused at 100 mg/min. Exendin-4 (1 nmol) was given as an intravenous bolus at 60, 120 and 180 min. Exendin(9-39) amide, 42 nmol, was given together with exendin-4 at 120 min. The first phase of insulin release is greatly reduced and the second phase is abolished by this ratio of antagonist to agonist.
FIG. 4 is a graph illustrating the effect of exendin on cultured beta cells. βTC-3 cell insulin response to exendin-4, insulin mg/well vs. exendin-4 logM.
FIG. 5 is a graph demonstrating the effect of exendin antagonist on glucose -stimulated increase in insulin. Conscious dog infused with glucose at 200 mg/min beginning at time 0. A bolus injection of exendin(9-39) amide was made at 60 minutes.
FIG. 6 is a graph illustrating the effect of Y31 exendin-4(1-31) amide. Conscious, fasted dog injected with a bolus of Y31 exendin-4(1-31) amide at time 0.
FIG. 7 is a graph illustrating the effect of GLP-1 with and without antagonist. Insulin responses in a fasted dog to GLP-1 (1 nmol) injected either alone at time 0 or together with exendin(9-39) amide (180 nmol) at time 60 min. GLP-1's insulinotropic activity is inhibited by exendin (9-39) amide.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides for novel polypeptides which are unexpectedly useful as insulinotropic agents. Insulinotropic agents being agents which can stimulate, or cause the stimulation of, the synthesis or expression of the hormone insulin. The polypeptides of the present invention are termed exendin-3 and exendin-4. These peptides were originally isolated from the venom of Heloderma horridum and Heloderma suspectum respectively. In one embodiment of the invention, polypeptides corresponding to the amino acid sequence of exendin-3 and exendin-4 are synthesized by the solid phase method as previously described (Merrifield, J. M., Chem. Soc. 85: 2149 (1962); Stewart and Young, Solid Phase Peptide Synthesis, Freeman, San Francisco, 1969, pp. 27-66). In addition, it is also possible to isolate naturally occuring polypeptides from venom samples in a fashion similar to the original isolation of exendins 3 and 4. It is further possible to obtain the desired polypeptides by using recombinant DNA techniques (Maniatis, T. et al., Molecular Biology: A Laboratory Manual, Cold Spring Harbor, N.Y., 1982). The invention encompasses polypeptides which are insulinotropic and can be derived from naturally-occuring amino acid sequences. These proteins consist of the following amino acid sequences:
Exendin-3 [SEQ ID No:1] HSDGTFTSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPPS
Exendin-4 [SEQ ID No:2] HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPPS
The invention also encompasses the insulinotropic fragments of exendin-4 comprising the amino acid sequentes:
Exendin-4(1-31) [SEQ ID No:3] HGEGTFTSDL SKQMEEAVR LFIEWLKNGG P
y31 Exendin-4(1-31 ) [SEQ ID No:4] HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG Y
The invention also encompasses the inhibitory fragment of exendin-4 comprising the amino acid sequence:
Exendin-4(9-39 ) [SEQ ID No:5] DL SKQMEEEAVR LFIEWLKNGG PSSGAPPPS
The invention further encompasses a method for the enhancement of insulin production or expression which comprises the steps of providing to a mammalian beta type pancreatic islet cell an effective amount of the insulinotropic peptides disclosed above.
Also provided for by the present invention are those amino acid sequences in the above peptides which are capable of functioning as insulinotropic hormones. In addition, the invention also provides for the addition of amino acids to enhance attachment to carrier molecules, or added to enhance the insulinotropic effect.
A material is said to be "substantially free of natural contaminants" if it has been substantially purified from materials with which it is normally and naturally found. Examples of natural contaminants of exendin-3 or exendin-4 are: other peptides, carbohydrates, glycosylated peptides, lipids, membrane, other venom components etc. A material is also said to be substantially free of natural contaminants if these contaminants are substantially absent of from a sample of the material.
The compounds of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions. In these compositions, exendin-3 and or exendin-4, or their functional derivatives are combined in admixture with a pharmaceutically acceptable carrier vehicle. Suitable vehicles and their formulations, inclusive of other human proteins, e.g. human serum albumin, are well known. In order to form an effective pharmaceutical composition, the composition will contain an effective amount of the exendin-3 or exendin-4, or functional derivatives together with a suitable amount of carrier vehicle. Other compositions may combine exendin-3 and exendin-4, or their functional derivatives with other effective drugs that may treat other symptoms, or the same symptoms.
The use of exendin-3 and 4 in compositions that may be injected intravenously, intramuscularly, subcutaneously, or intraperitoneally, would call for dosages of about 0. 1 pg/kg to 1,000 mg/kg body weight depending on many individual factors such as age, severity of disease, total body weight, sex and other mitigating factors.
The insulinotropic properties of a compound may be determined by in vitro or in vivo assay. The compound in question may be administered to animals and monitoring the release of insulin. It is possible to monitor the increase in insulin production in cell culture as well.
The sequences of the invention also provide a means for identifying any specific mamalian analogs to the exendins. This can be accomplished by direct comparison of amino acid sequences, or by the translation of RNA or DNA sequences which may encode for the amino acid sequences of the invention, or by inhibition of activity by the specific exendin inhibitor, exendin (9-39) amide.
The sequences of the invention also provides a means for generating antibodies specific for the exendins, and further for the production of monoclonal antibodies for the exendins and fragments thereof. Thus the invention provides a means for purifying mammalian or other analogs to the exendins by the method of affinity chromatography.
Testing was done to establish if exendin-3 or exendin-4 could stimulate pancreatic insulin secretion in mammals. Since both exendin-3 and exendin-4 peptides have about 50% homology with glucagon and GLP-1(7-36) (glucagon-like peptide-1), and GLP-1(7-36) was found to bind to exendin receptors, it was thought possible that exendins could act in similar fashion as GLP-1 on other receptors.
TABLE 1__________________________________________________________________________Exendin-3 HSDGTFTSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPPSExendin-4 HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPPSGLP-1 HAEGTFTSDV SSYLEGOAAK EFIAWLVKGRGlucagon HSQGTFTSDY SKYLDSRRAQ DFVQWLMNT__________________________________________________________________________
Polypeptides corresponding to the amino acid sequence of exendin-3 and exendin-4 were synthesised by the solid phase method as previously described (Merrifield, J. M., Chem. Soc. 85:2149 (19625; Stewart and Young, Solid Phase Peptide Synthesis, Freeman, San Francisco, 1969, pp. 27-66). It is also possible to isolate naturally occuring polypeptides from venom samples in a fashion similar to the original isolation of exendins 3 and 4. It is further possible to obtain the desired polypeptides by using recombinant DNA techniques (Maniatis,T. et al., Molecular Biology: A Laboratory Manual, Cold Spring Harbor, N.Y., 19825).
The examples which follow are illustrative of specific embodiments of the invention, and various uses thereof. They are set forth for explanatory purposes only, and are not to be taken as limiting the invention.
The exendins are insulinotropins
Naural or synthetic exendin-3 and exendin-4 were tested in several biological systems, including conscious dog, anesthetized dog with chronic indwelling left atrial catheters, and beta TC-3 insulinoma cell line (described in D'Ambra et al., Endocrinology 126:2815-2822 (1990)) in cell culture. FIG. 1 shows an insulin secretory response to bolus injection of exendin-3 in a conscious dog with a seven-fold increase in insulin concentration above basal levels. Similar results are obtained using exendin-4. Since exendin-4 does not interact with VIP receptors and acts solely on exendin receptors, it has been used for subsequent studies.
Exendin-4 insulin secretagogue activity is glucose dependent
Dogs with glucose concentrations clamped at graded levels show a glucose-dependent insulinotropic response to exendin-4. Dosages of exendin-4 which do not stimulate insulin release at fasting glucose concentrations of 50-75 mg/dL (such as 0.1 nmol exendin-4 given as a bolus) are able to produce a peak insulin response of one-fold above basal when given to dogs in a clamped, hyperglycemic state.
Exendin-4 stimulates a greater insulin secretory response than GLP-1
Synthetic exendin-4 was compared with GLP-1 (purchased from Peninsula Labs, Belmont, Calif.) by alternating injections of bolus doses into dogs with chronic indwelling left atrial catheters. Since GLP-1 and exendin-4 are glucose dependent in their insulinotropic response, paired equimolar doses of GLP-1 and exendin-4 were given with GLP-1 administered first to avoid the possibility that falling glucose levels in the animals cause a diminished insulinotropic response to GLP-1 relative to exendin-4. Dogs #1 and #2 in FIGS. 2a and 2b maintained constant fasting glucose concentrations throughout the experiments in a range between 60 and 80 mg/dL. FIGS. 2a, 2b and 2c show a comparison of insulinotropic responses to alternating bolus injections of GLP-1 and exendin-4 at 20 minute intervals and at increasing doses ranging from 0.1 nmol to 10 nmol administered through chronic indwelling left atrial catheters into anesthetized dogs.
In contrast to the euglycemia present in the first two dogs, the third dog in FIG. 3c was exceptionally hyperglycemic, probably as a result of an infected catheter. Several points are illustrated by this experiment. First, euglycemic dogs normally do not respond to 0.1 nmol of either GLP-1 or exendin-4 with an insulin secretory resonse as illustrated by the first two dogs, whereas the hyperglycemic dog had clear insulinotropic responses to this lower dose of peptide. Second, the rapid normalization of hyperglycemia to euglycemic levels following modest doses of the two peptides reflects the great potential for use of these peptides in treatment of diabetic states. Third, despite the rapid normalization of the hyperglycemia, hypoglycemia does not occur. This class of therapeutic agents might be termed "euglycemic" agents. The potential for hypoglycemia caused by overdosages of these agents is minimized. Hypoglycemia is avoided even when the agents are given in the euglycemic state. Fourth, despite the administration of exendin-4 following an equivilent dose of GLP-1 in the setting of decreasing glucose levels, the insulin response as defined by area under the curve, is consistently 2-3 fold greater for exendin-4 compared to GLP-1. The greater response to exendin-4 holds true for the two euglycemic animals as well. A summary of the insulin responses is shown in Table 2.
TABLE 2______________________________________Dog Dose AUC (GLP-1) AUC (EX-4) EX-4/GLP-1______________________________________#1 1 nmol 2.0 4.1 2.1#2 1 nmol 2.8 7.3 2.6#3 1 nmol 5.0 12.9 2.610 nmol 5.7 14.2 2.5______________________________________
Table 2 shows the relative ratio of insulin secretion stimulated by serial injections of GLP-1 (7-36) amide and exendin-4 expressed as area under the curve (AUC). AUC=T-B where T=total insulin secreted (sum of concentrations at times 2,4,6, 10 mad 14 min. and B=baseline insulin=average of insulin concentrations at times 0 and 20 min. Multiplied by a factor of 5.
Exendin(9-39) amide inhibits endogenous, exendin-4, and GLP-1 insulinotropic activity.
Antagonistic peptides can arise by a number of mechanisms. The gene encoding the exendins may also encode for related peptides which have antagonistic activity. The production of antagonistic peptides may then be either initiated or suppressed by differential cleavage of the pre-propeptide. The antagonistic peptides may also arise through post-translational modification of the agonist peptide, specifically through differential cleavage to produce extended or truncated forms of the agonist peptide. In our studies of the structure-function relationship of exendin peptide sequences, the NH2 -terminally truncated exendin analog, exendin(9-39) amide, was shown to have potent antagonistic activity against exendin-3 and exendin-4 in a pancreatic acinar cell system measuring cAMP activity. (Raufman et al., J. Biol. Chem. 266:2897-2902 (1991); Eng et al., J. Biol. Chem. 267:7402-7505 (1992)). FIG. 5 shows the effect of exendin(9-39) amide when administered alone on circulating insulin levels while glucose levels are clamped at approximately 100% above fasting levels. Following injection of the antagonist there is a rapid decrease in circulating insulin levels to 60% of the maximum concentration. This result indicates that the antagonist inhibited an endogenous insulinotropin that accounted for a substantial portion of the insulin secretory response to hyperglycemia.
When exendin(9-39) amide is given together with exendin-4 at a molar ratio of 40:1, there is substantial inhibition of the insulin secretory response, as shown in FIG. 3. The second phase of insulin release is completely inhibited while the first phase is more resistant to complete inhibition. This finding suggests a differential sensitivity to inhibition between the first and second phases of insulin release. A pathological condition which may correlate to this phenomenon is a loss of first phase insulin secretion in type 2 diabetes.
When exendin(9-39) amide is given together with GLP-1 at molar ratio of 180:1 there is substantial inhibition of the insulin secretory response, as shown in FIG. 7.
Exendin-4 acts directly on the beta cell
Beta TC-3 cells were obtained through Norman Fleischer (Diabetes Research and Training Center, Albert Einstein College of Medicine, N.Y.) and cultured in serum-containing media in 48-well culture dishes to confluency. Fresh media was added 24 hours before the cells were tested. The cells were tested in Earle's balanced salt solution containing IBMX, BSA and 16.7 mM glucose with graded concentrations of exendin-4 for 1 hour at 37° C. before collection of media supernate and assay for insulin concentrations. FIG. 4 shows a dose response curve to exendin-4 indicating that exendin-4 acts directly on beta cells to stimulate insulin secretion.
Exendin-4 reduces the hyperglycemic state in a diabetic animal model
The db/db mouse is a genetically obese and diabetic strain of mouse. The db/db mouse develops hyperglycemia and hyperinsulinemia concomitant with its development of obesity and thus serves as a model of obese type 2 diabetes (NIDDM). Five 11-week old db/db mice purchased from The Jackson Laboratories (Bar Harbor, Me.) had sub-orbital sinus blood samples taken before and 60 minutes after intraperitoneal injection of exendin-4 at 10 nmol each animal (1 microgram/gram body weight). Blood glucose measurements were made with a glucose meter (YSI 1500 glucose analyzer, Yellow Springs, Ohio). The blood glucose levels in the animals were (average±standard error, in mg/dL glucose) 310±37 before and 181±37 one hour after administration of exendin-4. Thus, exendin-4 was able to reduce the diabetic levels of blood glucose by 40% in these animals.
We have compared the effect of COOH-terminal truncations on the insulinotropic activity of exendin-4. The Y31 mutation of exendin-4(1-31) amide has a TYR for PRO substitution at position 31 from the amino terminus. This mutant was shown to have insulinotropic activity when infused into dog. FIG. 6 shows this result. This result indicates that the amino acids in the exendin-4 sequence located between residues 1 and 31 are important for the insulinotropic activity.
This invention thus provides for compounds that are an unexpectedly efficient means of stimulating insulin production in vitro and in vivo that will be useful for the treatment of diabetes mellitus, as well as specific inhibitors therof.
__________________________________________________________________________SEQUENCE LISTING(1) GENERAL INFORMATION:(iii) NUMBER OF SEQUENCES: 7(2) INFORMATION FOR SEQ ID NO:1:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 39 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(ix) FEATURE:(A) NAME/KEY: Peptide(B) LOCATION: 1..39(D) OTHER INFORMATION: /label=Exendin-3(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:HisSerAspGlyThrPheThrSerAspLeuSerLysGlnMetGluGlu151015Gl uAlaValArgLeuPheIleGluTrpLeuLysAsnGlyGlyProSer202530SerGlyAlaProProProSer35(2) INFORMATION FOR SEQ ID NO:2:(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(ix) FEATURE:(A) NAME/KEY: Peptide(B) LOCATION: 1..39(D) OTHER INFORMATION: /label=Exendin-4(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:HisGlyGluGlyThrPheThr SerAspLeuSerLysGlnMetGluGlu151015GluAlaValArgLeuPheIleGluTrpLeuLysAsnGlyGlyProSer20 2530SerGlyAlaProProProSer35(2) INFORMATION FOR SEQ ID NO:3:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 31 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: peptide (ix) FEATURE:(A) NAME/KEY: Peptide(B) LOCATION: 1..31(D) OTHER INFORMATION: /label=Exendin-1-31/note="Exendin-4(1-31)"(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:HisGlyGluGlyThrPheThrSerAspLeuSerLysGlnMetGluGlu15 1015GluAlaValArgLeuPheIleGluTrpLeuLysAsnGlyGlyPro202530(2) INFORMATION FOR SEQ ID NO:4:(i) SEQUENCE CHARACTERISTICS:( A) LENGTH: 31 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(ix) FEATURE:(A) NAME/KEY: Peptide(B) LOCATION: 1..31(D) OTHER INFORMATION: /label=Y31-Exendin4/note="Y-31-Exendin-4(1-31)"(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:HisGlyGluGlyT hrPheThrSerAspLeuSerLysGlnMetGluGlu151015GluAlaValArgLeuPheIleGluTrpLeuLysAsnGlyGlyTyr20 2530(2) INFORMATION FOR SEQ ID NO:5:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 31 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(ix) FEATURE:(A) NAME/KEY: Peptide(B) LOCATION: 1..31 (D) OTHER INFORMATION: /label=Exendin-9-39/note="Exendin-4(9-39)"(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:AspLeuSerLysGlnMetGluGluGluAlaValArgLeuPheIleGlu151015Trp LeuLysAsnGlyGlyProSerSerGlyAlaProProProSer202530(2) INFORMATION FOR SEQ ID NO:6:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 30 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single (D) TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(ix) FEATURE:(A) NAME/KEY: Peptide(B) LOCATION: 1..30(D) OTHER INFORMATION: /label=GLP-1-7-36/note="GLP-1(7-36) fragment"(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:HisAlaGluGlyThrPheThrSerAspValSerSerTyrLeuGluGl y151015GlnAlaAlaLysGluPheIleAlaTrpLeuValLysGlyArg202530(2) INFORMATION FOR SEQ ID NO:7:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 29 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(ix) FEATURE:(A) NAME/KEY: Peptide(B) LOCATION: 1..29(D) OTHER INFORMATION: /label=Glucagon(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:HisSerGln GlyThrPheThrSerAspTyrSerLysTyrLeuAspSer151015ArgArgAlaGlnAspPheValGlnTrpLeuMetAsnThr20 25
|1|| *||Eng, J. et al., Isolation and Characterization of Exendin 4, an Exendin 3 Analogue, from Heloderma suspectum Venom; J. Biol. Chem. 267:7402 (1992).|
|2||Eng, J. et al., Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from Heloderma suspectum Venom; J. Biol. Chem. 267:7402 (1992).|
|3|| *||Eng, J. et al., Purification and Structure of Exendin 3, a New Pancreatic Secretagogue Isolated from Heloderma horridum Venom; J. Biol. Chem. 265:20259 (1990).|
|4||Eng, J. et al., Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated from Heloderma horridum Venom; J. Biol. Chem. 265:20259 (1990).|
|5|| *||Gutniak, M. et al., Antidiabetogenic Effect of Glucagon Like Peptide 1 (7 36) Amide in Normal Subjects and Patients with Diabetes Mellitus; The New England J. Med. 326:1316 (1992).|
|6||Gutniak, M. et al., Antidiabetogenic Effect of Glucagon-Like Peptide-1 (7-36) Amide in Normal Subjects and Patients with Diabetes Mellitus; The New England J. Med. 326:1316 (1992).|
|7|| *||J. Eng & C. Eng, Exendin 3 and 4 are Insulin Secretagogues; Regulatory Peptides 40: 142 (1992).|
|8||J. Eng & C. Eng, Exendin-3 and -4 are Insulin Secretagogues; Regulatory Peptides 40: 142 (1992).|
|9|| *||John Eng, Exendin Peptides; The Mt. Sinai J. of Med. 59: 147 (1992).|
|10|| *||Raufman, J. P., Exendin 3 a Novel Peptide from Heloderma horridum Venom, Interacts with Vasoactive Intestinal Peptide Receptors and a Newly Described Receptor on Dispersed Acini from Guinea Pig Pancreas; J. Biol. Chem. 266:2897 (1991).|
|11||Raufman, J. -P., Exendin-3 a Novel Peptide from Heloderma horridum Venom, Interacts with Vasoactive Intestinal Peptide Receptors and a Newly Described Receptor on Dispersed Acini from Guinea Pig Pancreas; J. Biol. Chem. 266:2897 (1991).|
|12|| *||Raufmann, J. P., et al., Truncated Glucagon like Peptide 1 Interacts with Exendin Receptors on Dispersed Acini from Guinea Pig Pancreas; J. Biol. Chem. 267:21432 (1992).|
|13||Raufmann, J. -P., et al., Truncated Glucagon-like-Peptide-1 Interacts with Exendin Receptors on Dispersed Acini from Guinea Pig Pancreas; J. Biol. Chem. 267:21432 (1992).|
|14|| *||Schmidt et al. 1985. Diabetologia 28:704 707.|
|15||Schmidt et al. 1985. Diabetologia 28:704-707.|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US5846937 *||Mar 3, 1997||Dec 8, 1998||1149336 Ontario Inc.||Method of using exendin and GLP-1 to affect the central nervous system|
|US5958909 *||Nov 20, 1996||Sep 28, 1999||The General Hospital Corporation||Insulinotropic hormones and uses thereof|
|US6162907 *||Jun 5, 1998||Dec 19, 2000||The General Hospital Corporation||Dna and amino acid sequence of derivative of glucagon-like peptide i; antidiabetic agents for treatment of type ii diabetes mellitus|
|US6284727||Jun 7, 1995||Sep 4, 2001||Scios, Inc.||Polypeptide on a polymer carrier; antidiabetic agent|
|US6448045||Mar 10, 2000||Sep 10, 2002||The Regents Of The University Of California||Expressing a pdx-1 gene in cells that have been cultured under conditions such that the cells are in contact with other cells in the culture; contacting the cells with a glp-1 receptor agonist, thereby inducing insulin gene expression|
|US6506724||Jun 1, 1999||Jan 14, 2003||Amylin Pharmaceuticals, Inc.||Exendins are peptides that were first isolated from the salivary secretions of the Gila-monster, a lizard found in Arizona and have some sequence similarity to several members of the glucagon-like peptide|
|US6528486||Jul 12, 2000||Mar 4, 2003||Zealand Pharma A/S||Peptide agonists of GLP-1 activity|
|US6703359 *||Feb 5, 1999||Mar 9, 2004||Amylin Pharmaceuticals, Inc.||Treating toxic hypervolemia, renal failure, congestive heart failure, nephrotic syndrome, pulmonary edema, and hypertension|
|US6723530 *||Feb 5, 1998||Apr 20, 2004||Amylin Pharmaceuticals, Inc.||Polynucleotides encoding proexendin, and methods and uses thereof|
|US6767887 *||Jun 5, 1997||Jul 27, 2004||Roche Diagnostics Gmbh||Peptides that stimulate release of insulin; treating diabetes|
|US6828303||Aug 31, 2001||Dec 7, 2004||Scios, Inc.||Treatment of noninsulin dependent diabetes mellitus in a mammal by administering a sustained-release form of a glucagon-like protein (GLP-1 (7-37) having insulintropic activity; drug delivery|
|US6849708||Aug 10, 2000||Feb 1, 2005||The General Hospital Corporation||Insulinotropic hormone and uses thereof|
|US6852690 *||Aug 22, 1996||Feb 8, 2005||Amylin Pharmaceuticals, Inc.||Improved parenteral administration of nutrients is provided. The method comprises co- administration of nutrients, especially carbohydrates, and an insulinotropic peptide, or its derivatives, analogs, and fragments. The method and|
|US6858576 *||Aug 8, 1997||Feb 22, 2005||Amylin Pharmaceuticals, Inc.||Methods for regulating gastrointestinal motility|
|US6872700 *||Jan 14, 2000||Mar 29, 2005||Amylin Pharmaceuticals, Inc.||Methods for glucagon suppression|
|US6884585||May 30, 2002||Apr 26, 2005||The Regents Of The University Of California||Induction of beta cell differentiation in human cells by stimulation of the GLP-1 receptor|
|US6899883 *||May 12, 1995||May 31, 2005||London Health Sciences Centre||Treatment of diabetes|
|US6902744||Jan 14, 2000||Jun 7, 2005||Amylin Pharmaceuticals, Inc.||Exendin agonist formulations and methods of administration thereof|
|US6911324||Oct 18, 2001||Jun 28, 2005||The Regents Of The University Of California||Induction of beta cell differentiation in human cells|
|US6924264 *||Apr 28, 2000||Aug 2, 2005||Amylin Pharmaceuticals, Inc.||chain extension of polypeptides using polymers selected from polyethylene glycol, polylactams, albumin, gelatin, acrylic polymers, fatty acids, polysaccharides, lipid and/or dextrans; antidiabetic agents|
|US6956026 *||Jan 7, 1998||Oct 18, 2005||Amylin Pharmaceuticals, Inc.||Use of exendins for the reduction of food intake|
|US6982248 *||May 9, 2001||Jan 3, 2006||Amylin Pharmaceuticals, Inc.||Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue|
|US6989148 *||Mar 29, 1999||Jan 24, 2006||John Dupre||Treatment of diabetes|
|US6989366 *||Jun 28, 2002||Jan 24, 2006||Amylin Pharmaceuticals, Inc.||Exendins, exendin agonists, and methods for their use|
|US7056734 *||Aug 10, 1999||Jun 6, 2006||The United States Of America As Represented By The Department Of Health And Human Services, Nih||Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof|
|US7078375 *||Oct 24, 1997||Jul 18, 2006||Peter Mose Larsen||Diabetes-mediating proteins and therapeutic uses thereof|
|US7084243||Jun 1, 2001||Aug 1, 2006||Eli Lilly And Company||Glucagon-like peptide-1 analogs|
|US7115569||Oct 15, 2004||Oct 3, 2006||Amylin Pharmaceuticals, Inc.||Exendins, exendin agonists, and methods for their use|
|US7119168||Jun 1, 2004||Oct 10, 2006||Bioprospecting Nb Inc.||Paralytic peptide for use in neuromuscular therapy|
|US7138375 *||Oct 14, 2004||Nov 21, 2006||Amylin Pharmaceuticals, Inc.||treating Type II diabetes, eating disorders, and insulin-resistance syndrome with exendin peptide analogs|
|US7138486||Jun 21, 2004||Nov 21, 2006||The General Hospital Corporation||Insulinotropic hormone derivatives and uses thereof|
|US7153825||Mar 18, 2005||Dec 26, 2006||Amylin Pharmaceuticals, Inc.||Administering an exendin modified with a polyethylene glycol, gelatin and/or albumin to increase its biological half-life; treating hyperglucagonemia and diabetes, especially type II diabetes|
|US7157555||Aug 6, 1998||Jan 2, 2007||Amylin Pharmaceuticals, Inc.||A polypeptide useful in the treatment of Type I and II diabetes; delaying and/or slowing gastric emptying; lowering plasma glucose levels|
|US7164005||Oct 17, 2003||Jan 16, 2007||Alkermes, Inc.||Microencapsulation and sustained release of biologically active polypeptides|
|US7220721||Nov 13, 1998||May 22, 2007||Amylin Pharmaceuticals, Inc.||Exendin agonist peptides|
|US7223725||Nov 13, 1998||May 29, 2007||Amylin Pharmaceuticals, Inc.||Exendin agonist compounds|
|US7226990 *||Jun 21, 2001||Jun 5, 2007||Novo Nordisk A/S||Extendin derivatives|
|US7273850||Aug 21, 2006||Sep 25, 2007||Bioprospecting Nb Inc.||Administering to the cell all or part of a peptide isolated from the submaxiliary saliva glands of shrews of the species Blarina as a paralytic agent for inhibiting calcium uptake by a cancer cell|
|US7276352||Jan 19, 2005||Oct 2, 2007||The Regents Of The University Of California||Induction of β cell differentiation in human cells by stimulation of the GLP-1 receptor|
|US7297761 *||Jul 19, 2004||Nov 20, 2007||Amylin Pharmaceuticals, Inc.||Pharmaceutical compositions containing exendins|
|US7307148||Apr 22, 2005||Dec 11, 2007||Conjuchem Biotechnologies Inc.||Method for purification of albumin conjugates|
|US7329646||Nov 7, 2003||Feb 12, 2008||Shanghai Huayi Bio-Lab Co., Ltd.||recombinant methods;|
|US7393827||Dec 30, 2005||Jul 1, 2008||Diakine Therapeutics, Inc.||biological response modifier (lisofylline) and a beta -cell growth factor (exendin-4 or exenatide) in admixture with a pharmaceutically acceptable carrier; for treating Type 1 diabetes, autoimmune diabetes, or insulin dependent diabetes mellitus|
|US7399489||Nov 10, 2005||Jul 15, 2008||Amylin Pharmaceuticals, Inc.||Exendin analog formulations|
|US7407932||Oct 19, 2006||Aug 5, 2008||Amylin Pharmaceuticals, Inc.||Exendin agonist composed of a peptide in which at least one amino acid residue is acylated with a dicarboxylic acid; the amino acid residues are an internal lysine residue, an N-terminal amino acid residue, and/or a C-terminal amino acid residue; treatment of glucagonoma|
|US7419952||Mar 3, 2006||Sep 2, 2008||Amylin Pharmaceuticals, Inc.||Use of exendins and agonists thereof to treat diabetes|
|US7442680||Sep 5, 2003||Oct 28, 2008||Amylin Pharmaceuticals, Inc.||Inotropic and diuretic effects of GLP-1 and GLP-1 agonists|
|US7442682||Sep 2, 2005||Oct 28, 2008||Nitto Denko Corporation||disclosed for the treatment of diabetes and related diseases using peptides with incretin hormone activity. Preferably, the peptide with incretin hormone activity is GLP-1, exendin or an analog of GLP-1 or exendin. The peptides with incretin hormone activity are administered transepithelially hormones|
|US7452858||Nov 17, 2005||Nov 18, 2008||Amylin Pharmaceuticals, Inc.||Administering exendin, or an antagonist thereof; reducing blood glucose concentration|
|US7456254||Apr 13, 2005||Nov 25, 2008||Alkermes, Inc.||polyglycolic acid or polylactic acid or glycolic acid-lactic acid copolymer as biocompatible polymer having dispersed therein about 3%-5% (w/w) exendin-4 and about 2% (w/w) sucrose; antidiabetic agent|
|US7462365||Oct 17, 2003||Dec 9, 2008||Costantino Henry R||specific combination of excipients exhibits an increase of bioavailability of the polypeptide; namely a sugar and salting-out salt are present in sustained release composition|
|US7485622||Nov 18, 2003||Feb 3, 2009||Bioprospecting Nb Inc.||Paralytic peptide for use in neuromuscular therapy|
|US7498308||May 18, 2006||Mar 3, 2009||Eli Lilly And Company||The analogs are resistant to diaminopeptidase IV degradation and bind zinc; are active over an extended time in vivo|
|US7521423 *||Jul 20, 2004||Apr 21, 2009||Amylin Pharmaceuticals, Inc.||Exendin pharmaceutical compositions|
|US7524530||Apr 19, 2007||Apr 28, 2009||Alkermes, Inc.||Combining exendin and sucrose with oil phase comprising glycolic acid-lactic acid copolymer in methylene chloride to form emulsion, which is combined with coacervation agent (silicone oil) to form microparticles, transferring to quenching solvent, then hardening; sustained release; shelf life|
|US7531323||Jul 18, 2006||May 12, 2009||Peter Mose Larsen||Diabetes-mediating proteins and therapeutic uses thereof|
|US7544657||Oct 2, 2003||Jun 9, 2009||Zealand Pharma A/S||Stabilized Exendin-4 compounds|
|US7563871||Sep 14, 2006||Jul 21, 2009||Alkermes, Inc.||Polymer-based sustained release device|
|US7569540 *||May 10, 2004||Aug 4, 2009||Amylin Pharmaceuticals, Inc.||method for maximal parenteral nutrition substantially without acute or chronic hyperglycemia; includes a source of nutrients (carbohydrates) and an insulinotropic peptide (Glucagon-like-peptides, exendin)|
|US7608587||Aug 1, 2006||Oct 27, 2009||Changzhou Pharmaceutical Factory||Exendin 4 polypeptide fragment|
|US7608692||Apr 11, 2008||Oct 27, 2009||Amylin Pharmaceuticals, Inc.||or exendin-4 agonists covalently bonded to albumin, polyethylene glycol, gelatin, (hydroxypropyl)-methacrylamide, a polyamino acid, fatty acid, polysaccharide, dextran to increase molecular size; diabetes, postprandial dumping syndrome, postprandial hyperglycemia, dyslipidemia, obesity; renal filtration|
|US7612176||Jul 16, 2007||Nov 3, 2009||Alkermes, Inc.||Polymer-based sustained release device|
|US7683030||Mar 11, 2008||Mar 23, 2010||Amylin Pharmaceuticals, Inc.||Methods of treating diabetes with albumin-conjugated exendin peptides|
|US7691963||Apr 11, 2008||Apr 6, 2010||Amylin Pharmaceuticals, Inc.||or exendin-4 agonists covalently bonded to albumin, polyethylene glycol, gelatin, (hydroxypropyl)-methacrylamide, a polyamino acid, fatty acid, polysaccharide, dextran to increase molecular size; diabetes, postprandial dumping syndrome, postprandial hyperglycemia, dyslipidemia, obesity; renal filtration|
|US7696161||May 25, 2007||Apr 13, 2010||Amylin Pharmaceuticals, Inc.||Exendin agonist compounds|
|US7700549||Aug 29, 2008||Apr 20, 2010||Amylin Pharmaceuticals, Inc.||treating Type II diabetes, eating disorders, and insulin-resistance syndrome with exendin peptide analogs of given amino acid sequence|
|US7737251||Dec 23, 2005||Jun 15, 2010||Conjuchem Biotechnologies Inc.||conjugates comprising blood proteins covalently coupled to a gastrointestinal tissue growth promoter derivatives, having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders|
|US7741269 *||Jul 20, 2004||Jun 22, 2010||Amylin Pharmaceuticals, Inc.||Exendins and exendin agonists for weight reduction and obesity|
|US7741286||Feb 8, 2006||Jun 22, 2010||Conjuchem Biotechnologies Inc.||kringle peptides; peptidase stabilized|
|US7745588||Aug 7, 2007||Jun 29, 2010||Bioprospecting Nb Inc.||Antibodies to a paralytic peptide|
|US7785297||Feb 3, 2004||Aug 31, 2010||Novo Nordisk A/S||Injection device with rotatable dose setting|
|US7858740||Aug 28, 2006||Dec 28, 2010||Amylin Pharmaceuticals, Inc.||A polypeptide useful in the treatment of Type I and II diabetes; delaying and/or slowing gastric emptying; lowering plasma glucose levels|
|US7867972||Jul 24, 2007||Jan 11, 2011||Pharmacia & Upjohn Company, Llc||exendin-4 fused to a transferrin (Tf) via a polypeptide linker; for treatment of Type II diabetes, obesity, and to reduce body weight|
|US7875310||Mar 20, 2009||Jan 25, 2011||Alkermes, Inc.||Residual solvent extraction method and microparticles produced thereby|
|US7888314||Aug 5, 2005||Feb 15, 2011||Amylin Pharmaceuticals, Inc.||Compositions and methods for treating peripheral vascular disease|
|US7893017||Oct 7, 2005||Feb 22, 2011||Novo Nordisk A/S||Protracted GLP-1 compounds|
|US7906146||Feb 20, 2009||Mar 15, 2011||Amylin Pharmaceuticals, Inc.||Lyophilized formulations of exendins and exendin agonist analogs|
|US7919109||Mar 11, 2008||Apr 5, 2011||Intarcia Therapeutics, Inc.||Apparatus for uniform delivery of drugs to biological systems|
|US7928065||Oct 7, 2008||Apr 19, 2011||Amylin Pharmaceuticals, Inc.||Methods of treatment using exendin peptides or GLP-1 peptides|
|US7939494||Apr 9, 2009||May 10, 2011||Emisphere Technologies, Inc.||Method for administering GLP-1 molecules|
|US7974373||Mar 13, 2007||Jul 5, 2011||Pine Valley Investments, Inc.||Method and architecture for digital pulse shaping and rate conversion|
|US7981861||Jun 23, 2010||Jul 19, 2011||Amylin Pharmaceuticals, Inc.||Method of performing angioplasty with a GLP-1 molecule|
|US8003754||Jun 3, 2010||Aug 23, 2011||Soricimed Biopharma Inc.||Paralytic peptide for use as a insecticide|
|US8008255 *||May 28, 2004||Aug 30, 2011||Amylin Pharmaceuticals, Inc.||Methods and compositions for enhanced transmucosal delivery of peptides and proteins|
|US8026210||Jan 14, 2009||Sep 27, 2011||Amylin Pharmaceuticals, Inc.||Exendins and exendin agonist analogs to regulate gastrointestinal motility|
|US8030273 *||Oct 7, 2005||Oct 4, 2011||Novo Nordisk A/S||Protracted exendin-4 compounds|
|US8039432||Nov 9, 2006||Oct 18, 2011||Conjuchem, Llc||Method of treatment of diabetes and/or obesity with reduced nausea side effect|
|US8057822 *||Jun 30, 2005||Nov 15, 2011||Amylin Pharmaceuticals, Inc.||Modified exendins and exendin agonists|
|US8076288||Aug 17, 2005||Dec 13, 2011||Amylin Pharmaceuticals, Inc.||Hybrid polypeptides having glucose lowering activity|
|US8080516||Jun 29, 2005||Dec 20, 2011||Conjuchem, Llc||Long lasting synthetic exendin-4 peptide conjugates|
|US8084414||Aug 30, 2005||Dec 27, 2011||Conjuchem, Llc||Methods involving long lasting synthetic exendin-4-peptide conjugates|
|US8093206||Dec 14, 2005||Jan 10, 2012||Conjuchem, Llc||Methods involving long lasting synthetic exendin-4 peptide conjugates|
|US8114632 *||Jun 20, 2007||Feb 14, 2012||Biocon Limited||Method of producing biologically active polypeptide having insulinotropic activity|
|US8119405 *||May 24, 2004||Feb 21, 2012||Sarah Ferber||Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues|
|US8129339 *||Nov 6, 2008||Mar 6, 2012||Alkermes Pharma Ireland Limited||Microencapsulation and sustained release of biologically active polypeptides|
|US8158579||Nov 30, 2010||Apr 17, 2012||Biorexis Pharmaceutical Corporation||Fusion protein of an exendin to modified transferrin|
|US8173150||Mar 8, 2011||May 8, 2012||Intarcia Therapeutics, Inc.||Stable non-aqueous single phase viscous vehicles and formulations utlizing such vehicles|
|US8187672||Dec 14, 2010||May 29, 2012||Alkermes Pharma Ireland Limited||Residual solvent extraction method and microparticles produced thereby|
|US8211857||Sep 20, 2010||Jul 3, 2012||Soricimed Biopharma Inc.||Peptide composition for cancer treatment by inhibiting TRPV6 calcium channel activity|
|US8236760 *||Apr 24, 2008||Aug 7, 2012||Cedars-Sinsai Medical Center||Use of GLP-1 receptor agonists for the treatment of short bowel syndrome|
|US8263550||Dec 2, 2010||Sep 11, 2012||Amylin Pharmaceuticals, Inc.||Exendin agonist compounds|
|US8268341||Apr 23, 2012||Sep 18, 2012||Intarcia Therapeutics, Inc.||Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles|
|US8278272||Dec 18, 2008||Oct 2, 2012||The United States Of America, As Represented By The Secretary, Department Of Health & Human Services||GLP-1, exendin-4, peptide analogs and uses thereof|
|US8288338||Apr 23, 2010||Oct 16, 2012||Amylin Pharmaceuticals, Llc||Exendin and exendin agonists for eating disorders|
|US8293871||Apr 15, 2005||Oct 23, 2012||Alkernnes Pharma Ireland Limited||Poly(lactide-co-glycolide) based sustained release microcapsules comprising a polypeptide and a sugar|
|US8299025||Apr 22, 2008||Oct 30, 2012||Intarcia Therapeutics, Inc.||glucagon-like peptide-1; osmotic drug delivery device and method|
|US8329648||Apr 12, 2011||Dec 11, 2012||Amylin Pharmaceuticals, Llc||Methods for treating diabetes and reducing body weight|
|US8338136||Aug 1, 2011||Dec 25, 2012||Soricimed Biopharma Inc.||Method of producing a paralytic peptide|
|US8372424||Aug 28, 2012||Feb 12, 2013||Intarcia Therapeutics, Inc.||Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles|
|US8372804||Oct 24, 2008||Feb 12, 2013||Mannkind Corporation||Delivery of active agents|
|US8377869||Oct 24, 2008||Feb 19, 2013||Mannkind Corporation||Method of preventing adverse effects by GLP-1|
|US8378066||Oct 24, 2008||Feb 19, 2013||Corden Pharma Colorado, Inc.||Insulinotropic peptide synthesis using solid and solution phase combination techniques|
|US8389472||Aug 21, 2006||Mar 5, 2013||Amylin Pharmaceuticals, Llc||Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease|
|US8389473||Mar 30, 2010||Mar 5, 2013||Amylin Pharmaceuticals, Llc||Treatment of cardiac arrhythmias|
|US8419692||Jun 17, 2010||Apr 16, 2013||Novo Nordisk A/S||Injection device with rotatable dose setting|
|US8431685||Feb 25, 2010||Apr 30, 2013||Alkermes Pharma Ireland Limited||Polymer-based sustained release device|
|US8445647||Nov 14, 2011||May 21, 2013||Amylin Pharmaceuticals, Llc||Modified exendins and exendin agonists|
|US8461105||Sep 17, 2009||Jun 11, 2013||Alkermes Pharma Ireland Limited||Polymer-based sustained release device|
|US8466103||May 14, 2008||Jun 18, 2013||B&L Delipharm, Corp.||Exendin polypeptide linked to biotin, method for the preparation thereof and pharmaceutical composition comprising the same|
|US8492330||Jan 12, 2011||Jul 23, 2013||Emisphere Technologies, Inc.||Formulation comprising GLP-1|
|US8551947||Nov 12, 2010||Oct 8, 2013||Amylin Pharmaceuticals, Llc||Treatment of hibernating myocardium with an exendin peptide|
|US8575097||Apr 23, 2010||Nov 5, 2013||Pegbio Co., Ltd.||Exendin variant and conjugate thereof|
|US8614182||Jan 31, 2012||Dec 24, 2013||Jiangsu Hansoh Pharmaceuticals Co., Ltd.||GLP-1 analogues and their pharmaceutical salts and uses|
|US8617613||Apr 15, 2004||Dec 31, 2013||Alkermes Pharma Ireland Limited||Polymer-based sustained release device|
|US8618058||Jun 18, 2012||Dec 31, 2013||Soricimed Biopharma Inc.||Peptide composition for cancer treatment by inhibiting TRPV6 calcium channel activity|
|US8623817||Jan 17, 2012||Jan 7, 2014||Mannkind Corporation||Method of treating diabetes type 2 by administering ultrarapid acting insulin|
|US8673858||Dec 21, 2012||Mar 18, 2014||Soricimed Biopharma Inc.||Method for treating wrinkles using a paralytic peptide from the shrew Blarina brevicauda|
|US8680051 *||Dec 21, 2009||Mar 25, 2014||Qinghua Wang||Method of ameliorating symptoms of type 1-diabetes using GABA related compounds and GLP-1/exendin-4 compounds|
|US8697647||Dec 12, 2011||Apr 15, 2014||Odile Esther Levy||Hybrid polypeptides with selectable properties|
|US8759291||Apr 5, 2011||Jun 24, 2014||Amylin Pharmaceuticals, Llc||Methods of treatment using exendin peptides or GLP-1 peptides|
|US8772232||Aug 18, 2011||Jul 8, 2014||Novo Nordisk A/S||Protracted exendin-4 compounds|
|US8778899 *||May 12, 2004||Jul 15, 2014||Sarah Ferber||Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues|
|US8785381||Jul 2, 2009||Jul 22, 2014||Emisphere Technologies, Inc.||Oral GLP-1 formulations|
|US8785396||Nov 9, 2011||Jul 22, 2014||Mannkind Corporation||Method and composition for treating migraines|
|US8828953||Oct 19, 2010||Sep 9, 2014||NaZura BioHealth, Inc.||Chemosensory receptor ligand-based therapies|
|US8853160||Aug 24, 2012||Oct 7, 2014||The United States Of America, As Represented By The Secretary, Department Of Health & Human Services||GLP-1, exendin-4, peptide analogs and uses thereof|
|US8877252||Nov 22, 2013||Nov 4, 2014||Alkermes Pharma Ireland Limited||Polymer-based sustained release device|
|US8889099||Jan 30, 2013||Nov 18, 2014||Mannkind Corporation||Methods and compositions for delivering peptides|
|US8895498 *||Aug 22, 2012||Nov 25, 2014||Astrazeneca Pharmaceuticals, Lp||GIP and exendin hybrid polypeptides|
|US8906851||Dec 7, 2012||Dec 9, 2014||Amylin Pharmaceuticals, Llc||Method for treating diabetes|
|US8940316||Nov 15, 2010||Jan 27, 2015||Intarcia Therapeutics, Inc.||Osmotic delivery comprising an insulinotropic peptide and uses thereof|
|US8946149||Apr 11, 2006||Feb 3, 2015||Amylin Pharmaceuticals, Llc||Use of exendin and analogs thereof to delay or prevent cardiac remodeling|
|US8951962||May 17, 2013||Feb 10, 2015||Amylin Pharmaceuticals, Llc||Modified exendins and exendin agonists|
|US20100256056 *||Sep 5, 2008||Oct 7, 2010||Zheng Xin Dong||Analogues of exendin-4 and exendin-3|
|US20110144008 *||Dec 1, 2010||Jun 16, 2011||Bjarne Due Larsen||Peptide agonists of glp-1 activity|
|US20130137631 *||Aug 22, 2012||May 30, 2013||Amylin Pharmaceuticals, Llc||Gip analog and hybrid polypeptides with selectable properties|
|US20130331322 *||Aug 22, 2013||Dec 12, 2013||Astrazeneca Pharmaceuticals Lp||Exendins and exendin agonist analogs to regulate gastrointestinal motility|
|USRE41288 *||Aug 6, 2004||Apr 27, 2010||Amylin Pharmaceuticals, Inc.||increasing insulinotropic response in ischemia and treating reperfusion and injured brain cells after an ischemic event by administering glucagon-like peptide-1 and a pharmaceutical carrier for a time sufficient and under conditions effective to increase insulinotropic response which produces insulin|
|USRE45313||Jul 17, 2013||Dec 30, 2014||Zealand Pharma A/S||Exendin variant peptides|
|CN1318587C *||Jul 8, 2004||May 30, 2007||成都芝田生物工程有限公司||Recombination preparation method of amidating Exendin-4 polypeptide|
|CN100425284C||Jan 14, 2000||Oct 15, 2008||安米林药品公司||Methods for glucagon suppression|
|CN100429227C||Jun 29, 2005||Oct 29, 2008||常州制药厂有限公司||Exendin 4 polypeptide segment|
|CN101987868B||Jul 30, 2009||Sep 4, 2013||江苏豪森医药集团有限公司||Derivative or pharmaceutically acceptable salt of GLP-1 analogue and application of derivative or pharmaceutically-acceptable salt of a GLP-1 analogue|
|CN102421797B *||Jul 29, 2010||Dec 31, 2014||连云港豪森生物医药有限公司||Glp-1类似物的衍生物或其可药用盐和用途|
|DE102004043153A1 *||Sep 3, 2004||Mar 23, 2006||TransMIT Gesellschaft für Technologietransfer mbH||Erfindung betreffend GLP-1 und Exendin|
|DE102004043153B4 *||Sep 3, 2004||Nov 21, 2013||Philipps-Universität Marburg||Erfindung betreffend GLP-1 und Exendin|
|DE102008051834A1||Oct 17, 2008||Apr 22, 2010||Sanofi-Aventis Deutschland Gmbh||Drug, useful e.g. for treating diabetes, preferably type-I or II and for controlling fasting, postprandial and/or postabsorptive plasma glucose concentration, comprises insulin and glucagon-like peptide-1 agonist|
|DE102008053048A1||Oct 24, 2008||Apr 29, 2010||Sanofi-Aventis Deutschland Gmbh||Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist|
|DE102009038210A1||Aug 20, 2009||Mar 3, 2011||Sanofi-Aventis Deutschland Gmbh||Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist|
|DE102010011919A1||Mar 18, 2010||Sep 22, 2011||Sanofi-Aventis Deutschland Gmbh||Liquid composition, useful for treating e.g. type II diabetes mellitus, and/or obesity, comprises a glucagon-like peptide-1 agonist and/or its salt e.g. exendin-4, optionally an adjuvant and methionine|
|EP0966297A1 *||Aug 8, 1997||Dec 29, 1999||Amylin Pharmaceuticals, Inc.||Methods for regulating gastrointestinal motility|
|EP1019077A1 *||Aug 6, 1998||Jul 19, 2000||Amylin Pharmaceuticals, Inc.||Novel exendin agonist compounds|
|EP1032587A1 *||Nov 13, 1998||Sep 6, 2000||Amylin Pharmaceuticals, Inc.||Novel exendin agonist compounds|
|EP1066314A1 *||Nov 13, 1998||Jan 10, 2001||Amylin Pharmaceuticals, Inc.||Novel exendin agonist compounds|
|EP1175443A1 †||Apr 28, 2000||Jan 30, 2002||Amylin Pharmaceuticals, Inc.||Modified exendins and exendin agonists|
|EP1386930A1 *||May 8, 2002||Feb 4, 2004||Shanghai Huayi Bio Lab||Derivatives of exendin|
|EP1509598A2 *||Apr 1, 2003||Mar 2, 2005||The Regents Of The University Of California||Induction of insulin expression|
|EP1629849A2 *||Jan 7, 1998||Mar 1, 2006||Amylin Pharmaceuticals, Inc.||Pharmaceutical compositions comprising exendins and agonists thereof|
|EP1634605A2||Mar 8, 2001||Mar 15, 2006||Novo Nordisk A/S||Treatment of dyslipidemia in a patient having type 2 diabetes|
|EP1658856A1||Jan 14, 2000||May 24, 2006||Amylin Pharmaceuticals, Inc.||Exendins for glucagon suppression|
|EP1840134A2||Feb 25, 1999||Oct 3, 2007||Novo Nordisk A/S||GLP-1 derivatives|
|EP1932535A2||Jul 29, 1999||Jun 18, 2008||Novo Nordisk A/S||Stimulation of beta cell profileration|
|EP1938830A1 *||Nov 13, 1998||Jul 2, 2008||Amylin Pharmaceuticals, Inc.||Novel exendin agonist compounds|
|EP1938831A1 *||Aug 6, 1998||Jul 2, 2008||Amylin Pharmaceuticals, Inc.||Novel exendin agonist compounds|
|EP1941900A1 *||Nov 13, 1998||Jul 9, 2008||Amylin Pharmaceuticals, Inc.||Novel exendin agonist compounds|
|EP1958623A1||Apr 15, 2005||Aug 20, 2008||Amylin Pharmaceuticals, Inc.||Poly(Lactide-Co-Glycolide)-based sustained release microcapsules comprising a polypeptide and a sugar|
|EP2016950A1||Aug 8, 1997||Jan 21, 2009||Amylin Pharmaceuticals, Inc.||Pharmaceutical composition comprising an exedin-4 peptide|
|EP2022505A2 *||Jul 30, 2002||Feb 11, 2009||The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services||GLP-1, exendin-4, peptide analogs and uses thereof|
|EP2028192A1||Jul 2, 2003||Feb 25, 2009||Zealand Pharma A/S||GLP-1 and methods for treating diabetes|
|EP2033662A1||Jan 18, 2005||Mar 11, 2009||Novo Nordisk Health Care AG||Transglutaminase mediated conjugation of peptides|
|EP2062593A2||Nov 29, 2001||May 27, 2009||Takeda Pharmaceutical Company Limited||Method for producing preparation containing bioactive peptide|
|EP2112161A2||Jul 12, 2000||Oct 28, 2009||Zealand Pharma A/S||Peptides that lower blood glucose levels|
|EP2133073A1||Apr 15, 2005||Dec 16, 2009||Amylin Pharmaceuticals, Inc.||Poly(lactide-co-glycolide)-based sustained release microcapsules comprising a polypeptide and a sugar|
|EP2241327A1||Mar 15, 2007||Oct 20, 2010||Novo Nordisk A/S||Mixtures of Amylin and Insulin|
|EP2264064A1||Apr 28, 2000||Dec 22, 2010||Amylin Pharmaceuticals Inc.||Modified exendins and exendin agonists|
|EP2298337A2||Dec 9, 2004||Mar 23, 2011||Novo Nordisk A/S||Regulation of food preference using GLP-1 agonists|
|EP2308847A1||Oct 9, 2009||Apr 13, 2011||EMC microcollections GmbH||Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases|
|EP2316446A1||May 31, 2005||May 4, 2011||Novo Nordisk A/S||Counteracting drug-induced obesity using GLP-1 agonists|
|EP2330124A2||Aug 11, 2006||Jun 8, 2011||Amylin Pharmaceuticals Inc.||Hybrid polypeptides with selectable properties|
|EP2330125A2||Aug 11, 2006||Jun 8, 2011||Amylin Pharmaceuticals, Inc.||Hybrid polypeptides with selectable properties|
|EP2347762A1||Aug 18, 2006||Jul 27, 2011||Amylin Pharmaceuticals, Inc.||Exendin for treating diabetes and reducing body weight|
|EP2359808A1||Aug 8, 2007||Aug 24, 2011||Intarcia Therapeutics, Inc||Osmotic delivery systems and piston assemblies|
|EP2363112A2||Aug 8, 2007||Sep 7, 2011||Intarcia Therapeutics, Inc||Osmotic delivery systems and piston assemblies|
|EP2368579A1||Jan 18, 2005||Sep 28, 2011||Novo Nordisk Health Care AG||Transglutaminase mediated conjugation of peptides|
|EP2377856A1||Jul 14, 2006||Oct 19, 2011||Novo Nordisk A/S||Urea glucokinase activators|
|EP2390264A1||Feb 10, 2006||Nov 30, 2011||Amylin Pharmaceuticals Inc.||GIP analog and hybrid polypeptides with selectable propperties|
|EP2392595A1||Feb 10, 2006||Dec 7, 2011||Amylin Pharmaceuticals Inc.||GIP analog and hybrid polypeptides with selectable properties|
|EP2394656A2||Nov 18, 2004||Dec 14, 2011||Novo Nordisk A/S||Propylene Glycol-containing peptide formulations which are optimal for production and for use in injection devices|
|EP2409569A2||Feb 7, 2003||Jan 25, 2012||Emisphere Technologies, Inc.||Method for administering GLP-1 molecules|
|EP2409707A1||Apr 15, 2004||Jan 25, 2012||Alkermes Pharma Ireland Limited||Polymer-based sustained release device|
|EP2417980A1||Feb 11, 2005||Feb 15, 2012||Amylin Pharmaceuticals Inc.||Hybrid polypeptides with selectable properties|
|EP2422806A2||Feb 11, 2005||Feb 29, 2012||Amylin Pharmaceuticals Inc.||Hybrid polypeptides with selectable properties|
|EP2422807A2||Feb 11, 2005||Feb 29, 2012||Amylin Pharmaceuticals Inc.||Hybrid polypeptides with selectable properties|
|EP2444397A1||Jan 6, 2005||Apr 25, 2012||Novo Nordisk A/S||Heteroaryl-ureas and their use as glucokinase activators|
|EP2505207A2||Jan 10, 2006||Oct 3, 2012||Wuxi Grandchamp Pharmaceutical Technology Co., Ltd.||Modified exendins and uses thereof|
|EP2526971A1||May 25, 2011||Nov 28, 2012||ArisGen SA||Mucosal delivery of drugs|
|EP2554183A1||Nov 11, 2010||Feb 6, 2013||Sanofi-Aventis Deutschland GmbH||Pharmaceutical composition comprising a GLP-1-agonist, an insulin, and methionine|
|EP2605013A1||Jun 7, 2006||Jun 19, 2013||The Rockefeller University||Stimulation of pancreatic beta-cell proliferation|
|EP2636680A2||May 25, 2007||Sep 11, 2013||Amylin Pharmaceuticals, LLC||Composition and methods for treatment of congestive heart failure|
|EP2650006A1||Sep 5, 2008||Oct 16, 2013||Ipsen Pharma S.A.S.||Analogues of exendin-4 and exendin-3|
|WO1997046584A1 *||Jun 5, 1997||Dec 11, 1997||Boehringer Mannheim Gmbh||Exendin analogues, processes for their preparation and medicaments containing them|
|WO1998030231A1 *||Jan 7, 1998||Jul 16, 1998||Amylin Pharmaceuticals Inc||Use of exendins and agonists thereof for the reduction of food intake|
|WO1998035033A1 *||Feb 4, 1998||Aug 13, 1998||Ontario Inc 1149336||Polynucleotides encoding proexendin, and methods and uses thereof|
|WO1998039022A1 *||Mar 3, 1998||Sep 11, 1998||Ontario Inc 1149336||Methods of using exendin and glp-1, and agonists and antagonists thereof, to affect the central nervous system|
|WO1999007404A1 *||Aug 6, 1998||Feb 18, 1999||Amylin Pharmaceuticals Inc||Novel exendin agonist compounds|
|WO1999025728A1 *||Nov 13, 1998||May 27, 1999||Amylin Pharmaceuticals Inc||Novel exendin agonist compounds|
|WO1999040788A1 *||Feb 5, 1999||Aug 19, 1999||Amylin Pharmaceuticals Inc||Inotropic and diuretic effects of exendin and glp-1|
|WO1999043708A1 *||Feb 25, 1999||Sep 2, 1999||Novo Nordisk As||Glp-1 derivatives of glp-1 and exendin with protracted profile of action|
|WO2000009666A2 *||Aug 10, 1999||Feb 24, 2000||Us Gov Health & Human Serv||Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof|
|WO2000041548A2 *||Jan 14, 2000||Jul 20, 2000||Amylin Pharmaceuticals Inc||Methods for glucagon suppression|
|WO2001068108A1 *||Mar 9, 2001||Sep 20, 2001||Dominique Dufayet||Induction of beta cell differentiation in human cells by stimulation of the glp-1 receptor|
|WO2002090388A1||May 8, 2002||Nov 14, 2002||Shanghai Huayi Bio Lab||Derivatives of exendin|
|WO2003072195A2||Feb 7, 2003||Sep 4, 2003||Lilly Co Eli||Method for administering glp-1 molecules|
|WO2004035623A2||Oct 2, 2003||Apr 29, 2004||Zealand Pharma As||Stabilized exendin-4 compounds|
|WO2004036186A2 *||Oct 17, 2003||Apr 29, 2004||Alkermes Inc||Microencapsulation and sustained release of biologically active polypeptides|
|WO2004069314A1||Jan 23, 2004||Aug 19, 2004||Steffen Hansen||Injection device with rotatable dose setting|
|WO2005023291A2 *||Sep 10, 2004||Mar 17, 2005||Lars Hansen||Use of glp1-agonists in the treatment of patients with type i diabetes|
|WO2005040195A2 *||Oct 22, 2004||May 6, 2005||Durga Annavajjula||Formulation of exendins|
|WO2005041873A2 *||Oct 25, 2004||May 12, 2005||Azopax Therapeutics Llc||Formulation of exendin-4|
|WO2005065714A1||Dec 17, 2004||Jul 21, 2005||Nastech Pharm Co||Intranasal administration of glucose-regulating peptides|
|WO2005066145A1||Jan 6, 2005||Jul 21, 2005||Novo Nordisk As||Heteroaryl-ureas and their use as glucokinase activators|
|WO2005070468A2||Jan 18, 2005||Aug 4, 2005||Novo Nordisk As||Transglutaminase mediated conjugation of peptides|
|WO2005100388A1 *||Apr 18, 2005||Oct 27, 2005||Biocon Ltd||Production of insulinotropic peptides|
|WO2006058923A1||Dec 5, 2005||Jun 8, 2006||Novo Nordisk As||Heteroaromatic glucokinase activators|
|WO2007000118A1||Jun 29, 2006||Jan 4, 2007||Changzhou Pharmaceutical Facto||Exendin 4 polypeptide fragments and use thereof|
|WO2007006814A1||Jul 14, 2006||Jan 18, 2007||Novo Nordisk As||Urea glucokinase activators|
|WO2007056907A1||Mar 30, 2006||May 24, 2007||Dalian D N Bio Engineering Co||TRUNCATED GLUCAGON-LIKE PEPTIDE-1 (sGLP-1) AND ITS PREPARING METHOD AND USE|
|WO2007104786A1||Mar 15, 2007||Sep 20, 2007||Novo Nordisk As||Mixtures of amylin and insulin|
|WO2007124463A1 *||Apr 20, 2007||Nov 1, 2007||Amgen Inc||Glp-1 compound/glucagon antibody compositions|
|WO2008084044A1||Jan 8, 2008||Jul 17, 2008||Novo Nordisk As||Urea glucokinase activators|
|WO2009010428A1||Jul 9, 2008||Jan 22, 2009||Novo Nordisk As||Protease stabilized, pegylated insulin analogues|
|WO2009053315A1 *||Oct 17, 2008||Apr 30, 2009||Hoffmann La Roche||Insulinotropic peptide synthesis using solid and solution phase combination techniques|
|WO2009107900A1 *||May 14, 2008||Sep 3, 2009||Sungkyunkwan University Foundation For Corporate Collaboration||Exendin derivative linked biotin, method for the preparation thereof and pharmaceutical composition comprising the same|
|WO2009143285A2||May 20, 2009||Nov 26, 2009||Amylin Pharmaceuticals, Inc.||Exendins to lower cholestrol and triglycerides|
|WO2010121559A1||Apr 23, 2010||Oct 28, 2010||Pegbio Co., Ltd.||Novel exendin variant and conjugate thereof|
|WO2010140148A1||Jun 1, 2010||Dec 9, 2010||Yeda Research And Development Co . Ltd||Prodrugs containing albumin binding probe|
|WO2011012080A1 *||Jul 29, 2010||Feb 3, 2011||Jiangsu Hansoh Pharmaceutical Group Co., Ltd.||Derivative of glp-1 analogue or its pharmaceutical salts and their use|
|WO2011024110A2||Aug 19, 2010||Mar 3, 2011||Rinat Neuroscience Corporation||Glucagon-like peptide-1 receptor (glp-1r) agonists for treating autoimmune disorders|
|WO2011048614A2||Oct 18, 2010||Apr 28, 2011||Cadila Healthcare Limited||Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist|
|WO2011058082A1||Nov 11, 2010||May 19, 2011||Sanofi-Aventis Deutschland Gmbh||Pharmaceutical composition comprising a glp-1 agonist and methionine|
|WO2011058083A1||Nov 11, 2010||May 19, 2011||Sanofi-Aventis Deutschland Gmbh||Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine|
|WO2011063414A1||Nov 23, 2010||May 26, 2011||Amylin Pharmaceuticals, Inc.||Polypeptide conjugate|
|WO2011064316A2||Nov 25, 2010||Jun 3, 2011||Paolo Botti||Mucosal delivery of peptides|
|WO2011104378A1||Feb 28, 2011||Sep 1, 2011||Novo Nordisk A/S||Peptides for treatment of obesity|
|WO2011107447A1||Mar 1, 2011||Sep 9, 2011||Novo Nordisk A/S||Preparative rp-hplc method for purifying peptides|
|WO2011117415A1||Mar 28, 2011||Sep 29, 2011||Novo Nordisk A/S||Novel glucagon analogues|
|WO2011117416A1||Mar 28, 2011||Sep 29, 2011||Novo Nordisk A/S||Novel glucagon analogues|
|WO2011162989A2||Jun 10, 2011||Dec 29, 2011||Vanderbilt University||Glp-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction|
|WO2012050923A2||Sep 28, 2011||Apr 19, 2012||Amylin Pharmaceuticals, Inc.||Engineered polypeptides having enhanced duration of action|
|WO2012140647A2||Apr 4, 2012||Oct 18, 2012||Yeda Research And Development Co. Ltd||Albumin binding probes and drug conjugates thereof|
|WO2012168474A1||Jun 11, 2012||Dec 13, 2012||Monell Chemical Senses Center||Novel methods|
|WO2013041678A1||Sep 21, 2012||Mar 28, 2013||Novo Nordisk A/S||Novel glucagon analogues|
|WO2013049234A2||Sep 26, 2012||Apr 4, 2013||Novartis Ag||Dual function proteins for treating metabolic disorders|
|WO2013050378A1||Oct 2, 2012||Apr 11, 2013||Sanofi-Aventis Deutschland Gmbh||Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract|
|WO2013050379A1||Oct 2, 2012||Apr 11, 2013||Sanofi-Aventis Deutschland Gmbh||Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the pancreatic duct system|
|WO2013064669A1||Nov 2, 2012||May 10, 2013||Zealand Pharma A/S||Glp-1 receptor agonist peptide gastrin conjugates|
|WO2013083826A2||Dec 10, 2012||Jun 13, 2013||Novo Nordisk A/S||Glp-1 agonists|
|WO2013090454A2||Dec 12, 2012||Jun 20, 2013||Receptos, Inc.||Novel glp-1 receptor modulators|
|WO2013103384A1||Jul 11, 2012||Jul 11, 2013||Elcelyx Therapeutics, Inc.||Biguanide compositions and methods of treating metabolic disorders|
|WO2013158928A2||Apr 18, 2013||Oct 24, 2013||Elcelyx Therapeutics, Inc.||Chemosensory receptor ligand-based therapies|
|WO2013170636A1||May 17, 2013||Nov 21, 2013||Adda Biotech Inc.||Protein and protein conjugate for diabetes treatment, and applications thereof|
|WO2013186240A2||Jun 12, 2013||Dec 19, 2013||Sanofi||Exendin-4 peptide analogues|
|WO2013192131A1||Jun 18, 2013||Dec 27, 2013||Indiana University Research And Technology Corporation||Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function|
|WO2014064215A1||Oct 24, 2013||May 1, 2014||INSERM (Institut National de la Santé et de la Recherche Médicale)||TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL|
|Oct 1, 2012||AS||Assignment|
Owner name: AMYLIN PHARMACEUTICALS, INC., CALIFORNIA
Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:ELI LILLY AND COMPANY;REEL/FRAME:029057/0626
Effective date: 20120808
|Jun 22, 2012||AS||Assignment|
Owner name: AMYLIN PHARMACEUTICALS, INC., CALIFORNIA
Effective date: 20120621
Free format text: SECURITY AGREEMENT;ASSIGNOR:ELI LILLY AND COMPANY;REEL/FRAME:028428/0819
|Mar 29, 2011||CC||Certificate of correction|
|Jan 11, 2011||B1||Reexamination certificate first reexamination|
Free format text: THE PATENTABILITY OF CLAIMS 5 AND 6 IS CONFIRMED. CLAIMS 1-4 AND 7 ARE CANCELLED. NEW CLAIMS 8-14 ARE ADDED AND DETERMINED TO BE PATENTABLE.
|Nov 24, 2009||RR||Request for reexamination filed|
Effective date: 20090821
|Dec 13, 2006||FPAY||Fee payment|
Year of fee payment: 12
|Sep 27, 2004||AS||Assignment|
Owner name: AMYLIN PHARMACEUTICALS, INC., CALIFORNIA
Free format text: PATENT AND TECHNOLOGY LICENSE AGREEMENT;ASSIGNOR:ENG, DR. JOHN;REEL/FRAME:015177/0815
Effective date: 19961001
Owner name: AMYLIN PHARMACEUTICALS, INC. 9373 TOWNE CENTRE DRI
Free format text: PATENT AND TECHNOLOGY LICENSE AGREEMENT;ASSIGNOR:ENG, DR. JOHN /AR;REEL/FRAME:015177/0815
|Oct 8, 2003||AS||Assignment|
Owner name: ELI LILLY AND COMPANY, INDIANA
Free format text: SECURITY INTEREST;ASSIGNOR:AMYLIN PHARMACEUTICALS, INC.;REEL/FRAME:015394/0483
Effective date: 20030630
Owner name: ELI LILLY AND COMPANY LILLY CORPORATE CENTERINDIAN
Free format text: SECURITY INTEREST;ASSIGNOR:AMYLIN PHARMACEUTICALS, INC. /AR;REEL/FRAME:015394/0483
|Nov 15, 2002||FPAY||Fee payment|
Year of fee payment: 8
|Sep 30, 1998||FPAY||Fee payment|
Year of fee payment: 4